

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2025 Commission File No. 001-39621 OPTHEA LIMITED (Translation of registrant's name into English)
Level 4 650 Chapel Street South Yarra, Victoria, 3141 Australia (Address of registrant's principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F
EXHIBIT INDEX Exhibit
Description 99.1 Opthea to Present at Oppenheimer Healthcare Conference
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
OPTHEA LIMITED (Registrant)
By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 02/07/2025 EX-99.1 Exhibit
99.1 ASX, Nasdaq and Media Release February 7, 2025 Opthea to Present at Oppenheimer Healthcare Conference Melbourne, Australia, and Princeton, NJ, US, February 7, 2025 -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimer's 35th Annual Healthcare Life Sciences Conference Date: February 11-12, 2025 Presentation: Tuesday, February 11, 2025, 10:00 AM ET Webcast Link: <https://wsw.com/webcast/oppenheimer39/opt/2588856> The webcast will also be accessible on the "Events & Presentations" section of the Company's website at <http://ir.opthea.com/>.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone. To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries Join our email database to receive program updates: PJ KelleherLifeSci Advisors LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430 7579
Media Inquiries Silvana Guerri-LenaNorthStream Global Partners Email: silvana@nsgpllc.com Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited